Avacopan (CCX168), a C5a receptor antagonist, has been shown to ameliorate anti-myeloperoxidase -induced necrotizing crescentic glomerulonephritis in murine models, supporting its mechanistic role in crescentic glomerulonephritis.95 The gene discussed is MPO; the disease is crescentic glomerulonephritis.